by Francisca Peixoto | Jan 5, 2023 | Uncategorized
As we start the new year, LifeLink Ventures releases its 2022 Annual Biotech Report. We wish to connect private investors with emerging technologies that address global health challenges. To do so, first we must bring our investors closer to the biotech world. Learn...
by Francisca Peixoto | Nov 15, 2022 | Uncategorized
The BioTech Breakthrough Awards recognizes “the world’s best life sciences and biotech companies, their products and their services” and, in the 2nd annual BioTech Breakthrough Awards, our portfolio company Chameleon Biosciences has been named Immunomodulatory...
by Francisca Peixoto | Oct 28, 2022 | Uncategorized
Ochre Bio has announced their Scientific Strategy Board. This group of brilliant minds recently spent a day together in New York, to talk through Ochre’s scientific approach and future planning. Sangeeta Bhatia – Wilson Professor of Engineering, MIT...
by Francisca Peixoto | Mar 3, 2022 | Uncategorized
We are pleased to announce that our portfolio company Accure Therapeutics signed an exclusive worldwide licensing agreement with Oculis to develop and commercialise a potentially disease modifying therapy to protect and prevent damage to the optic nerve and retina....
by Francisca Peixoto | Dec 22, 2021 | Uncategorized
As the year comes to a close, LifeLink Ventures releases its Annual Biotech Report. We wish to connect private investors with emerging technologies that address global health challenges. To do so, first we must bring our investors closer to the biotech world. Learn...
by Francisca Peixoto | Jun 16, 2021 | Uncategorized
Our portfolio company CEBINA was founded with the aim of creating, nurturing, and promoting early-stage life sciences companies in central Europe. CEBINA incubates and accelerates promising projects in the biotech field. Now, CEBINA has joined forces with the...
